Literature DB >> 2114423

The costs of smoking and the cost effectiveness of smoking-cessation programs.

A Elixhauser.   

Abstract

The impact of cigarette smoking on morbidity and mortality in this country is enormous. It is the cause of one out of every six deaths in the U.S., and is linked to conditions ranging from cardiovascular disease to cancer to low-birth weight. Economic analyses indicate that cessation of cigarette smoking will probably not lead to reduced health care expenditures in the general population because of increased health care utilization during those years of life saved as a result of cessation. However, when indirect costs (economic productivity) are taken into account, cessation of cigarette smoking appears to be cost saving. In addition, for particular subgroups (such as pregnant women and post-myocardial infarction patients), there may be health-care cost savings. Cost-effectiveness analyses of smoking cessation methods are reviewed. A relatively narrow range of smoking cessation methods has been evaluated for cost effectiveness. There is some evidence that cost-effective smoking cessation programs are tailored to the target population and consist of multiple interventions with reinforcement of the cessation techniques or messages. Equity considerations demand that smoking cessation programs not be chosen simply on the basis of their cost effectiveness because it is likely that certain groups (such as minorities or heavy smokers) will not be targeted. Some potentially efficacious smoking cessation methods such as bans on smoking in public places and excise taxes are not easily assessable using cost-effectiveness methodology.

Entities:  

Mesh:

Year:  1990        PMID: 2114423

Source DB:  PubMed          Journal:  J Public Health Policy        ISSN: 0197-5897            Impact factor:   2.222


  11 in total

1.  The reach and effectiveness of a national mass media-led smoking cessation campaign in The Netherlands.

Authors:  A N Mudde; H De Vries
Journal:  Am J Public Health       Date:  1999-03       Impact factor: 9.308

Review 2.  The economics of smoking: an overview of the international and New Zealand literature.

Authors:  D Phillips; I Kawachi; M Tilyard
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

Review 3.  Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage.

Authors:  K E Warner
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 4.  Autonomy, paternalism, and justice: ethical priorities in public health.

Authors:  David R Buchanan
Journal:  Am J Public Health       Date:  2007-11-29       Impact factor: 9.308

Review 5.  Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models.

Authors:  Kristian Bolin
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

Review 6.  Economic implications of smoking cessation therapies: a review of economic appraisals.

Authors:  D R Cohen; G H Fowler
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

7.  University-Based Smoking Cessation Program Through Pharmacist-Physician Initiative: An Economic Evaluation.

Authors:  Mohamed Izham Mohamed Ibrahim; Nagmeldien Ahmed Mohammed Magzoub; Norlela Maarup
Journal:  J Clin Diagn Res       Date:  2016-02-01

8.  Costs and effects associated with a community pharmacy-based smoking-cessation programme.

Authors:  G E Crealey; J C McElnay; T A Maguire; C O'Neill
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

9.  Improving Value-Based Care Education in a Fellowship by Incorporating ACGME Competencies.

Authors:  Kristine Zanotti; Sahana Somasegar; Monica Webb Hooper; Elizabeth Hopp
Journal:  J Grad Med Educ       Date:  2019-12

Review 10.  A review of economic evaluations of tobacco control programs.

Authors:  Jennifer W Kahende; Brett R Loomis; Bishwa Adhikari; Latisha Marshall
Journal:  Int J Environ Res Public Health       Date:  2008-12-28       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.